R H N van Schaik
Overview
Explore the profile of R H N van Schaik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1237
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hermans R, Gangapersad R, Kloosterboer S, van Schaik R, Hillegers M, Koch B, et al.
Eur Neuropsychopharmacol
. 2024 Apr;
85:5-7.
PMID: 38643629
No abstract available.
2.
de With M, Sadlon A, Cecchin E, Haufroid V, Thomas F, Joerger M, et al.
ESMO Open
. 2023 Mar;
8(2):101197.
PMID: 36989883
Background: The main cause for fluoropyrimidine-related toxicity is deficiency of the metabolizing enzyme dihydropyrimidine dehydrogenase (DPD). In 2020, the European Medicines Agency (EMA) recommended two methods for pre-treatment DPD deficiency...
3.
Pratt V, Cavallari L, Fulmer M, Gaedigk A, Hachad H, Ji Y, et al.
J Mol Diagn
. 2022 Aug;
24(10):1051-1063.
PMID: 35931343
The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing and a...
4.
Pratt V, Cavallari L, Del Tredici A, Gaedigk A, Hachad H, Ji Y, et al.
J Mol Diagn
. 2021 Jun;
23(9):1047-1064.
PMID: 34118403
The goals of the Association for Molecular Pathology Clinical Practice Committee's Pharmacogenomics (PGx) Working Group are to define the key attributes of pharmacogenetic alleles recommended for clinical testing, and to...
5.
Danesi R, Lo Y, Oellerich M, Beck J, Galbiati S, Del Re M, et al.
Clin Chim Acta
. 2021 Jun;
520:168-171.
PMID: 34081934
The analysis of circulating cell free DNA is an important tool for the analysis of tumor resistance, tumor heterogeneity, detection of minimal residual disease and detection of allograft rejection in...
6.
van Westrhenen R, van Schaik R, van Gelder T, Birkenhager T, Bakker P, Houwink E, et al.
Front Pharmacol
. 2021 May;
12:640032.
PMID: 33995044
Effective pharmacologic treatments for psychiatric disorders are available, but their effect is limited due to patients' genetic heterogeneity and low compliance-related to frequent adverse events. Only one third of patients...
7.
van Gelder T, van Schaik R
Ned Tijdschr Geneeskd
. 2020 Jul;
164.
PMID: 32608920
With the exception of a few medical specialties, the implementation of pharmacogenetic tests in daily practice has thus far been limited. The Royal Dutch Pharmacists Association (KNMP) has developed pharmacogenetics-based...
8.
van Westrhenen R, Bet P, van Weelden M, van Schaik R
Tijdschr Psychiatr
. 2020 Jan;
61(10):678-680.
PMID: 31907910
No abstract available.
9.
Andrews L, Hesselink D, van Schaik R, van Gelder T, de Fijter J, Lloberas N, et al.
Br J Clin Pharmacol
. 2018 Dec;
85(3):601-615.
PMID: 30552703
Aims: The aims of this study were to describe the pharmacokinetics of tacrolimus immediately after kidney transplantation, and to develop a clinical tool for selecting the best starting dose for...
10.
Danesi R, Del Re M, Ciccolini J, Schellens J, Schwab M, van Schaik R, et al.
Ann Oncol
. 2016 Oct;
28(1):183.
PMID: 27687313
No abstract available.